The Effect of Sugammadex on Prothrombin and Activated Partial Thromboplastin Time

Evangelia Samara; Konstantinos Stamatiou; Marina Balanika; Petros Tzimas

doi:10.7759/cureus.14521

The Effect of Sugammadex on Prothrombin and Activated Partial Thromboplastin Time

Cureus. 2021 Apr 16;13(4):e14521. doi: 10.7759/cureus.14521.

Authors

Evangelia Samara¹, Konstantinos Stamatiou², Marina Balanika¹, Petros Tzimas³

Affiliations

¹ Department of Anaesthesiology, Onassis Cardiac Surgery Center, Athens, GRC.
² Department of Urology, Tzaneio General Hospital of Piraeus, Piraeus, GRC.
³ Department of Anesthesiology and Postoperative Intensive Care, School of Health Sciences, University of Ioannina, Ioannina, GRC.

Abstract

Sugammadex is routinely used as an effective neuromuscular blockade reversal agent. Several studies have indicated that it may prolong the prothrombin time (PT) and the activated partial thromboplastin time (aPTT). This review gathers the relevant in vivo studies to accumulate knowledge on the subject. Nine studies were included. According to the results, sugammadex seems to lead to a transient increase in aPTT and PT values, compared to standard care. However, the clinical impact seems to be trivial. Nevertheless, the trials' findings reveal great heterogeneity, preventing a meta-analysis. Therefore, more well-designed studies are needed to lead to prudent conclusions.

Keywords: activated partial thromboplastin time (aptt); bleeding; coagulation; hemostasis; prothrombin time (pt); sugammadex.

Publication types

Review